It has been shown in preclinical and early clinical studies that blocking CXCR4 can disrupt the interaction between cancer cells and the microenvironment, preventing cancer cells from migrating to secondary sites (Zlotnik, 2008). This evidence concerns the gene CXCR4 and cancer.